Enter Wise Medicine: Innovation-Driven, Empowering Health

(Source: RuiZhi Pharmaceutical)

RuiZhi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “RuiZhi Pharmaceutical”) was established in 2000, and listed on the Shenzhen Stock Exchange in 2010 (stock code: 300149). The headquarters is located in the Zhangjiang Hi-Tech Park in Shanghai. The company provides full-cycle new drug R&D services and microecology and health services, covering the entire process from early discovery to commercialization and production of new drugs in chemical drugs and biologics. It has branches in the United States, the United Kingdom, Denmark, and various locations in China. The current Chairman and Chief Executive Officer (CEO) is Malaysian-Chinese entrepreneur Hu Rui Lian (Woo Swee Lian).

Hu Rui Lian (Woo Swee Lian)

The company’s predecessor was Quantum Hi-Tech (China) Biopharmaceutical Co., Ltd. In 2018, it completed the acquisition of Shanghai RuiZhi Chemistry, and in 2020 it adopted its current name. On May 6, 2025, the company announced that the controlling shareholder and the actual controller changed to Hu Rui Lian. In the first half of 2025, it achieved a net profit attributable to shareholders of RMB 25.3821 million; the proportion of orders for new modal drugs increased to 17%. On November 2025, it jointly with East China Normal University launched the first global drug manufacturing system for drug manufacturing of ADC, with core components’ domestic production rate exceeding 95%.

News reports

On September 14, 2024, the Deputy Prime Minister of Malaysia attended the signing ceremony for the strategic cooperation between RuiZhi Pharmaceutical and Universiti Kebangsaan Malaysia (UKM), and the inauguration ceremony of RuiZhi Pharmaceutical’s global innovation center for ADC drug manufacturing systems.

On September 30, 2024, RuiZhi Pharmaceutical, together with Jinan University’s National Key Laboratory, signed a framework agreement for strategic cooperation between RuiZhi Pharmaceutical and the National Key Laboratory of Bioactive Molecules and Pharmaceutical Property Optimization of Jinan University. The aim is to promote the transformation and validation of innovative drug R&D achievements, and to establish an innovative system integrating industry, academia, and research.

In the first quarter of 2024, RuiZhi Pharmaceutical achieved revenue of RMB 235 million, a year-on-year decrease of 12.68%, with a loss of RMB 25.4606 million. Afterwards, the company accelerated its transition to the field of innovative drug manufacturing. In 2025, its performance turned from loss to profit, and in November 2025 it achieved a technical breakthrough for the first global drug manufacturing system.

The company’s third-quarter report for 2025 shows that, in the first three quarters, revenue was RMB 817 million, a year-on-year increase of 13.7%; net profit attributable to shareholders successfully turned around from the year-ago loss of RMB 61.67 million, achieving net profit attributable to shareholders of RMB 7.09 million; non-recurring items net profit attributable to shareholders was a loss of RMB 14.35 million; net operating cash flow was RMB 120 million, up 6.8% year-on-year.

The company is advancing innovation such as one-stop “full package” services and microfluidic manufacturing systems, and accelerating its global expansion plans. At the same time, the overall industry turnaround of medical R&D outsourcing is occurring, and policy support for the development of innovative drugs continues.

On November 18, 2025, RuiZhi Pharmaceutical Technology Co., Ltd. announced that, together with East China Normal University, the world’s first drug manufacturing system applicable to ADC and nucleotide phosphoramidate monomer synthesis was released in Zhangjiang, Shanghai. By means of chip integration technology, the system enables fully continuous synthesis. Its core component domestic production rate exceeds 95%. The comprehensive cost is reduced by more than 50% compared with imported solutions. It was listed as an example of an “industry-academia-research-application integrated” ecosystem platform.

On January 30, 2026, RuiZhi Pharmaceutical released its 2025 annual performance forecast, expecting net profit attributable to shareholders of between RMB 12.30 million and RMB 18.45 million, turning losses into profits. It also clarified its strategic transition toward “innovation drug R&D partners.” Through the “full package” strategy, RuiZhi Pharmaceutical strengthened end-to-end capabilities from target discovery to IND. It also used the CVC model to lock in potential orders in advance with the help of an industry fund. Meanwhile, RuiZhi Pharmaceutical continued to enhance upgrades of its technology platforms and made progress in areas such as AI-assisted R&D and new modal drugs.

Corporate services

RuiZhi Pharmaceutical provides one-stop new drug R&D services from target discovery to process implementation, covering multiple R&D stages for both chemical drugs and biologics.

Chemical drug R&D: compound libraries, medicinal chemistry, synthetic chemistry, peptide chemistry, nucleoside/nucleotide chemistry, glycosylation chemistry, PROTAC, fragment-based screening (FBS), computer-assisted drug design, and analytical services.

Nucleotide synthesis process innovation:

Adopting a green reaction pathway with no catalysts and no involvement of bases, breaking through the traditional phosphoramidation process’s reliance on highly toxic catalysts and anhydrous, oxygen-free conditions. This enables all-weather continuous synthesis of monomers and resolves batch-to-batch quality fluctuation issues.

Early process development for small-molecule drugs (chemical synthesis and early process development):

route exploration, process development, synthesis from milligram to kilogram scale, fluid chemistry, analytical development support, and synthesis safety assessment.

Biologics R&D:

protein science, stable cell line construction, production and characterization of bispecific and multispecific antibodies, hybridoma antibody discovery platform, single B-cell cloning Beacon antibody discovery platform, phage display antibody discovery platform, antibody humanization and affinity maturation modification, developability assessment of antibody drugs, in vitro functional characterization, molecular interaction detection, and structural analysis of drug target protein complexes.

Biologics CDMO:

developability assessment, cell line development and banking, process development, formulation development, pilot-scale production, analysis and characterization, quality control (QC), quality assurance (QA), technology transfer, process characterization, process validation, commercial production, drug substance cGMP production, drug product cGMP production, and drug registration and submission.

Biology and pharmacodynamic efficacy:

in vitro biology, brain and behavioral pharmacology, cell biology, inflammation and immunology, oncology pharmacology, and in vitro neuropharmacology pharmacodynamics.

Pharmacokinetics and early toxicology:

in vitro drug metabolism, pharmacokinetics/pharmacodynamics (PK), early toxicology, tissue pathology and molecular pathology, bioanalysis, and formulations.

ADC/XDC R&D service platform:

antibody discovery, antibody engineering, linker-payload chemistry, biological conjugation and characterization (the company’s latest released ADC drug manufacturing system uses customized drug-manufacturing chip technology, integrating and directly chaining the deconjugation and conjugation processes traditionally performed step-by-step, achieving a fully continuous synthesis process; at the same time, it supports online monitoring and precise control of key quality attributes such as antibody ratio and free toxins, significantly shortening the process development cycle to several days), in vitro and in vivo pharmacodynamic evaluation, DMPK and early toxicology.

Translational medicine and clinical trial bioanalysis service platform:

development of bioanalytical methods for biomarkers and sample testing in preclinical research; bioanalysis PK/PD toxicology studies supporting IND submission; clinical trial bioanalysis PK/ADA/small-molecule drugs/Biomarker.

Corporate services

ADC/XDC R&D services

The company co-builds an AI drug manufacturing joint laboratory with East China Normal University, and in November 2025 jointly released a drug manufacturing system applicable to ADC and nucleotide monomer synthesis. In the ADC field, the system can shorten the traditional process development and optimization cycle that takes weeks by 70%, and enables online monitoring and precise control of key quality attributes such as DAR, free toxins, and aggregates, substantially reducing batch-to-batch differences. The system also reduces nucleotide monomer synthesis cost by more than 40%, and improves overall R&D service efficiency, forming a distinctive core competitiveness of AI+CRO.

Corporate profile

RuiZhi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “RuiZhi Pharmaceutical”) was established in 2000, and listed on the Shenzhen Stock Exchange in 2010 under stock code 300149. RuiZhi Pharmaceutical’s headquarters is located in the Zhangjiang Hi-Tech Park in Shanghai, China. It is an innovative company committed to integrated services of new drug R&D and production. The company’s business network spans the globe, with offices, R&D centers, and production bases in Zhangjiang, Shanghai; Jinqiao; Lingang New Area; Guangzhou, Guangdong; Qidong, Jiangsu; Chengdu, Sichuan; Boston, United States; Kent, United Kingdom; and Copenhagen, Denmark. It can provide global pharmaceutical companies, biotechnology companies, and research institutions with end-to-end integrated full-cycle services for new drug R&D, covering the entire process from early discovery to commercialization and production.

Since 2000, the group has been deeply engaged in the microecology industry. Its wholly owned subsidiary, Guangdong Hongyuan Pukang Medical Technology Co., Ltd., serves as a professional platform in the microecology and health sector and is one of the first batches of companies to enter this field in China. The company focuses on gut microbiota and the “Gut-X axis” technology, building a one-stop service system covering microbiome testing, metagenomics analysis, microecology preparations, intestinal bacteria transplantation technologies, and microecology drug R&D, as well as microecology health management. As the Secretary-General Unit of the Microecology Medical Professional Committee of the China Association for the Promotion of Scientific & Technological Industrialization, the company leads the development of the industry.

Office building

Office environment

RuiZhi Pharmaceutical Innovation Center

RuiZhi Pharmaceutical main building

In terms of the core management team, during Hu Rui Lian’s tenure as Chairman and CEO, RuiZhi Pharmaceutical advanced the “full package” order service model by building the one-stop service platform of “from target to IND,” promoting deep integration of AI and drug R&D, strengthening new modal drug capabilities such as ADC/XDC, peptides, small nucleic acids, and PROTAC, and promoting internationalization through platforms such as the Boston and Kent labs in the UK.

Since its establishment, RuiZhi Pharmaceutical has built a team of scientific research talent through frontier, diverse, and comprehensive technological accumulation, and has arranged research facilities, animal experimental facilities, and pharmaceutical intermediate production facilities. The company has approximately 110,000 square meters of pharmaceutical R&D and analytical laboratories, equipped with a large number of experimental instruments. In addition, it also has nearly 10,000 square meters of an animal testing center, which can provide experimental services for various animal species including monkeys, dogs, pigs, rabbits, guinea pigs, and mice/rats of different sizes.

RuiZhi Pharmaceutical has a series of comprehensive new drug R&D service platforms, ranging from drug target research, molecular design and screening, generation and optimization of lead compounds, and drug template design, to antibody drug discovery, drug metabolism and pharmacokinetics (DMPK) and pharmacological pharmacodynamic efficacy, as well as CMC development for preclinical/clinical and commercial stages. The drugs available for R&D services include chemical drugs, biologics, conjugate drugs (XDC), and more, covering multiple therapeutic areas including oncology, autoimmune diseases, neurological and psychiatric diseases, and digestive and metabolic diseases.

Development history

2000

RuiZhi Pharmaceutical Technology Co., Ltd. was originally—Jiangmen Quantum Hi-Tech Bioengineering Co., Ltd. was established.

2002

Pioneer Chemical was established, officially launching chemical drug CRO business.

2003

Shanghai RuiZhi was established, further expanding the chemical drug CRO business.

2010

The company was listed on the SME board of the Shenzhen Stock Exchange (stock code: 300149).

2015

The company was selected as one of the first batches of postdoctoral workstation approved in Guangdong Province, and also the only enterprise selected in the biological medicine field at that time. The postdoctoral scientific research station has always taken “helping lead innovation in the pharmaceutical and healthcare industry” as its mission, and is committed to building an integrated, high-end talent platform combining industry, academia, research, and application.

2018

Quantum Hi-Tech (300149) acquired Shanghai RuiZhi Chemical Research Co., Ltd., and the stock name was changed to “Quantum Bio.”

Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. was approved to become a supporting unit of the Microecology Medical Professional Committee of the China Association for the Promotion of Scientific & Technological Industrialization.

2019

RuiZhi Pharmaceutical Innovation Center located in Zhangjiang was officially put into operation, becoming the company’s global R&D center, operations center, and innovation source center.

2020

The company officially changed its name to “RuiZhi Pharmaceutical.”

2021

January 22: Hu Rui Lian was elected Chairman of the fourth session of the board of directors of RuiZhi Pharmaceutical.

2023

December 25: Hu Rui Lian was nominated as a candidate for non-independent director of the fifth session of the board of directors.

2024

January 10: Hu Rui Lian was re-elected as Chairman of the fifth session of the board of directors and appointed CEO.

May 26: Signed a cooperation agreement for the “China–Malaysia Biopharmaceutical Industry Park” with Meta Bright Group Berhad (Zhengyuan Group). Hu Rui Lian, Chairman and CEO of RuiZhi Pharmaceutical, participated in the signing. The Deputy Prime Minister of Malaysia attended as a witness.

August 9: Signed a Memorandum of Understanding (MOU) for cooperation with The Hong Kong Polytechnic University. The two parties formally established a partnership and began a new chapter of cooperation.

September 11: RuiZhi Pharmaceutical’s global ADC innovation center in Zhangjiang, Shanghai, was officially inaugurated. In the same period, RuiZhi Pharmaceutical signed a strategic cooperation agreement with Universiti Kebangsaan Malaysia (UKM), and signed an ADC customer agreement with Lixin Pharmaceutical. Hu Rui Lian, Chairman and CEO of RuiZhi Pharmaceutical, attended the unveiling and witnessed the signing. The Deputy Prime Minister of Malaysia and leaders from Zhangjiang Group attended and witnessed as well.

December: RuiZhi Pharmaceutical released an announcement that the current Chairman, WOO SWEE LIAN (Hu Rui Lian), will become the company’s actual controller.

2025

March 11: Signed an agreement with East China Normal University to co-build an “AI drug manufacturing joint laboratory,” jointly exploring an industry-academia-research cooperation mechanism of “artificial intelligence + biopharmaceuticals.”

March 19: Signed agreements with China Construction (Southeast Asia) Co., Ltd. and China International Economic Consulting Co., Ltd. to advance the biopharmaceutical industrial park project, focusing on R&D, manufacturing, logistics, and halal certification, and expanding into the Southeast Asian market.

May 6: RuiZhi Pharmaceutical’s announcement shows that the company’s controlling shareholder changed from Beihai Baben Venture Capital Co., Ltd. to WOO SWEE LIAN (Hu Rui Lian), and the actual controller changed accordingly to WOO SWEE LIAN (Hu Rui Lian).

June 27: RuiZhi Pharmaceutical reached a strategic cooperation with Saint No Pharmaceutical, jointly building an innovation ecosystem for small nucleic acid drugs.

July: The Chengdu RuiZhi Pharmaceutical biological medicine analysis and testing center passed the CNAS re-evaluation + scope expansion evaluation

July: RuiZhi Pharmaceutical reached a strategic cooperation with Lidao Pharmaceutical, jointly advancing the innovation drug R&D process.

August 8: Signed and entered the “International Headquarters Base of the National Technology Innovation Center for the Guangdong–Hong Kong–Macao Greater Bay Area” in the Shenzhen Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.

August 27: The company’s 2024 materials for a private placement of shares to specific investors were formally accepted by the SZSE.

September: Deepened strategic cooperation with Fosun Pharmaceutical’s global R&D center.

September 3: Its wholly owned subsidiary Beihai RuiZhi invested RMB 58 million (29%); together with partners including TouKong Donghai, it jointly established a biopharmaceutical industry fund with a total size of RMB 200 million, focusing on investing in innovative drugs and medical devices.

September 10: The Boston R&D center was officially launched. Experts including Nobel Prize winner Sir Richard John Roberts attended. The purpose is to empower pharmaceutical companies’ new drug R&D based on global professional capabilities.

October: Completed an ISO 27001:2022 certification upgrade.

November 17–18: Together with East China Normal University, RuiZhi Pharmaceutical released the world’s first drug manufacturing system applicable to ADC and nucleotide phosphoramidate monomer synthesis, achieving over 95% domestic production of the system’s core components. Academician Qian Xuhong of the Chinese Academy of Engineering and President of East China Normal University, and Hu Rui Lian, Chairman and CEO of RuiZhi Pharmaceutical, attended together.

November 25: In Shanghai, signed a framework strategic cooperation agreement with Fosun Pharmaceutical, linking key drug R&D links through complementary strengths.

November 28: Signed an agreement with Beijing Tsinghua Changgung Hospital to co-build an “organoid innovation center.”

December 9: Reached a strategic cooperation with the School of Pharmacy of Xi’an Jiaotong University and the Suzhou Research Institute to co-build an integrated innovation ecosystem integrating industry, academia, and research.

December 16: Strategically invested in Beijing Zheyuan Technology and reached cooperation with it. By integrating both parties’ resources and capabilities, effective combination of wet and dry experiments was achieved, driving deep integration of technology and R&D processes, improving drug discovery efficiency and the success rate of developability.

December 17: As a technical support party, participated in jointly launching a RMB 300 million small nucleic acid industry fund with Hangzhou Fuyang Economic Development Zone, Xin Yuan Zhenghe, and Saint No Pharmaceutical (02257.HK), to support the development of local industry clusters.

2026

January: RuiZhi Pharmaceutical officially joined the United Nations Global Compact (UNGC).

January 13: Announced that an automated integrated microfluidic synthesis system based on “limit-exceeding manufacturing” will be applied first to the internal platform, enabling ADC and small nucleic acid drug R&D, and further expanding into new modal business.

January 20: Chen Jiehui, General Manager of Sinopharm Guangzhou Pharmaceutical Group, led a research and exchange team. Both sides reached consensus on strategic cooperation and establishing a normalized communication and docking mechanism around pharmaceutical R&D and AI intelligent manufacturing.

February 9: Signed a strategic cooperation with Meigea Technology to co-build an “AI-driven biopharmaceutical automation laboratory,” promoting deep integration and implementation of AI technology in drug R&D.

March: Signed a framework strategic cooperation agreement with Hengqin Shenhui Industrial Investment, Everbright Zhiyuan Investment, and BeiGene. The four parties co-build the “Hongji Innovation Transformation Platform,” aiming to rely on the Hengqin Guangdong–Macao in-depth cooperation zone to jointly screen, empower, and incubate global early-stage biopharmaceutical innovation projects.

March 17: Subsidiary Guangdong Hongyuan Pukang acquired Shanghai Mobo Bio. Through this deal, RuiZhi Pharmaceutical deepened its microecology medical industry layout and entered a new stage of strategic development.

Company scale

As one of the well-established domestic CXO (pharmaceutical outsourcing) companies, RuiZhi Pharmaceutical can provide leading-level one-stop pharmaceutical R&D and production services for both biologics and chemical drugs. It has operational sites or branches in Shanghai, Jiangsu, Sichuan, and the United States and Europe.

Since its establishment, RuiZhi Pharmaceutical has built a team of scientific research talent through frontier, diverse, and comprehensive technological accumulation, and arranged research facilities, animal experimental facilities, and pharmaceutical intermediate production facilities. The company has approximately 110,000 square meters of pharmaceutical R&D and analytical laboratories, equipped with a large number of experimental instruments. In addition, it also has nearly 10,000 square meters of an animal testing center, which can provide experimental services for various animal species including monkeys, dogs, pigs, rabbits, guinea pigs, and mice/rats of different sizes. Over the past 20+ years, RuiZhi Pharmaceutical has provided full-scope one-stop drug R&D services to nearly 4,000 global pharmaceutical enterprises, biotechnology companies, and R&D institutions. It has established strategic cooperation relationships with more than 150 of the world’s top biopharmaceutical research institutions and companies. This essentially covers the world’s top 20 multinational big pharma companies, strongly supporting preclinical research for pharmaceutical companies both at home and abroad. Among more than 200 target new drug R&D projects in which RuiZhi Pharmaceutical has participated, many projects have already advanced to different milestone stages. RuiZhi Pharmaceutical participates in thousands of R&D projects every year and in nearly 100 new drug clinical research application submissions (IND) annually. As of 2024, it has successfully helped customers advance 15 new drugs from early R&D stages to global market launch, benefiting patients.

Corporate honors

Top 200 “Forbes Asia’s Best Small and Mid-sized Companies” in 2013;

Major drafting unit of the national standard for low-degree oligosaccharides (oligofructose).

“Quantum Hi-Tech and the design” was recognized as a well-known trademark in China.

2015

Won the European International Quality Management Gold Award (IAE)

2016

Ranked among the top 100 Innovation Brand Value of Listed Companies in China.

Won the Food and Beverage Industry · Jung Technology Innovation and Team Innovation Award

2017

Selected by People’s Daily as a “China’s invisible champion.”

2020

Based on “Research on product efficacy analysis and end-market promotion application of key technologies for typical prebiotics production,” it won the “Innovation Award” (Second Prize) in the Science and Technology awards of the China Association for the Promotion of Scientific & Technological Industrialization.

2024

At the first Future XDC New Drug Conference, RuiZhi Pharmaceutical won the honor of “ADC/Radiopharmaceutical New Infrastructure Pioneer Enterprise” for its outstanding contributions and innovation strength in new drug R&D.

RuiZhi Pharmaceutical was successfully selected in the 2024 China Life Sciences Service Enterprise Brand Top 100 list, demonstrating RuiZhi Pharmaceutical’s strong capabilities in the life sciences services sector and the industry’s high recognition of its professional expertise.

2025

Guangdong Hongyuan Pukang Medical Technology Co., Ltd. won the “Outstanding Contribution Award” in the Science and Technology awards of the China Association for the Promotion of Scientific & Technological Industrialization, based on the project “Research on precise matching for intestinal bacteria transplantation.”

At the 7th CMC-CHINA China Pharmaceutical Industry Expo in 2025, RuiZhi Pharmaceutical showcased its new results. From frontier presentations to technology exchange and needs matchmaking, it comprehensively demonstrated its hard-core capabilities and industry influence in pharmaceutical R&D. It won two awards: “2025 China New Drug Preclinical CRO TOP20” and “China Pharmaceutical CRO/CDMO Enterprise FNS101,” highlighting its hard-core strength in frontier R&D and excellent service.

On September 24, 2025, at the 2025 China Medical Drug Decision Makers Summit held in Beijing and other related events, the “China’s Innovation Drug Ten-Year Honor” list was unveiled. RuiZhi Pharmaceutical, based on its outstanding service quality, strong technical capabilities, forward-looking global expansion strategy, and continuous empowerment of industrial innovation, won the title of “Industry-leading CRO company.”

In October, awarded “Present to CHEMPARTNER Dedicated to Lifescience”

In December, awarded “Outstanding collaborator Award Chempartner Biology Department”

Mission and vision

Mission:

Empower pharmaceutical innovation in all dimensions so that life meets hope earlier

Vision:

Become a trusted partner for innovators in the global life sciences field

Massive information and precise interpretation—only on the Sina Finance app